Qiming Venture Partners

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Artavazd Arumov Ph.D

Principal

Cyrus Chan

Associate

Nan Chen

Principal

David Chu

Partner

Phillip DiGiacomo Ph.D

Principal

Past deals in Health Care

Singular Medical

Series C in 2025
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

Auron Therapeutics

Series B in 2025
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Leyden Labs

Series B in 2025
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

IntoCare

Series D in 2024
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

LTZ Therapeutics

Series A in 2024
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Chunyu Yisheng

Venture Round in 2024
Chunyu Yisheng, established in 2011 and headquartered in Beijing, is a mobile application designed to enhance communication between physicians and patients. The app allows doctors to access their patients' medical records and facilitates direct interaction, enabling patients to schedule appointments and communicate with their healthcare providers. Additionally, Chunyu Yisheng offers reservation line treatment services, further supporting users in managing their health. The company focuses on leveraging Internet technology to improve health outcomes and streamline the healthcare experience.

Ruining Bio

Series B in 2024
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

IntoCare

Series D in 2023
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

LTZ Therapeutics

Seed Round in 2023
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

CuroVax

Series B in 2023
CuroVax, established in 2011 and headquartered in Changzhou City, China, specializes in vaccine development and production. The company offers a range of vaccines, including a freeze-dried rabies vaccine for human use and an influenza virus split vaccine. CuroVax employs a dual approach of independent development and collaborative research, supported by multiple technology platforms such as large-scale mammalian cell culture and mRNA vaccine development. It provides biotechnology and microbiology services, focusing on improving health and medical industry standards.

Singular Medical

Series B in 2023
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

Sunny Dental

Series A in 2022
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a comprehensive range of orthodontic services. The company provides diagnosis and treatment for dental implants, children’s dentistry, dental restorations, periodontal disease, dental pulp issues, and oral and maxillofacial surgery. Sunny Dental is dedicated to offering professional care and advanced solutions in various aspects of dental health, ensuring a focus on both preventative and restorative treatments.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Boulder Care

Series B in 2022
Boulder Care, established in 2017 and headquartered in Portland, Oregon, specializes in telemedicine-based programs for opioid addiction treatment. The company offers comprehensive services including medication-assisted treatment with buprenorphine, peer support, patient counseling, and psychosocial services to aid recovery. Boulder Care serves patients directly, as well as healthcare providers and organizations seeking to expand access to effective opioid addiction treatment.

LTZ Therapeutics

Seed Round in 2022
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.

Ceptur Therapeutics

Series A in 2022
Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Ruining Bio

Series A in 2022
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

Shanzhen

Series D in 2021
ShanZhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups, personalized health management plans, and insurance options. Additionally, it offers medical examination services and data finance products aimed at mitigating the challenges posed by an aging population and the rising prevalence of chronic diseases. Through its comprehensive services, ShanZhen seeks to enhance the quality of life for elderly patients, promoting healthier and happier living conditions.

Structure Therapeutics

Series B in 2021
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

IntoCare

Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

IntoCare

Secondary Market in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Singular Medical

Series B in 2021
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

Auron Therapeutics

Seed Round in 2021
Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Wuli Planet

Series A in 2020
Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.

Structure Therapeutics

Series A in 2020
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Singular Medical

Series A in 2020
Singular Medical is a technology company focused on the research and development of cardiac rhythm management (CRM) products. It specializes in designing and industrializing a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. By creating a complete technical platform, Singular Medical offers solutions that encompass the entire patient journey, from initial detection of cardiac issues to ongoing follow-up care. The company's commitment to providing reliable and professional medical equipment aims to enhance the quality of care for patients with various cardiac conditions.

IntoCare

Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Sunny Dental

Series A in 2020
Sunny Dental, founded in 2007 and based in Beijing, China, specializes in a comprehensive range of orthodontic services. The company provides diagnosis and treatment for dental implants, children’s dentistry, dental restorations, periodontal disease, dental pulp issues, and oral and maxillofacial surgery. Sunny Dental is dedicated to offering professional care and advanced solutions in various aspects of dental health, ensuring a focus on both preventative and restorative treatments.

Shanzhen

Series D in 2019
ShanZhen is a health service platform focused on addressing the physical health and pension needs of individuals born in the 1980s and 1990s. The company provides affordable regular health checkups, personalized health management plans, and insurance options. Additionally, it offers medical examination services and data finance products aimed at mitigating the challenges posed by an aging population and the rising prevalence of chronic diseases. Through its comprehensive services, ShanZhen seeks to enhance the quality of life for elderly patients, promoting healthier and happier living conditions.

Structure Therapeutics

Series A in 2019
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule medicines for chronic diseases with high unmet medical needs. Its platform combines structure-based drug design, computational chemistry, and data integration to create orally available therapies that overcome limitations of biologics and peptide drugs. The company concentrates on targeting G-protein coupled receptors and other mechanisms, leveraging structural insights to identify differentiated, efficacious, and safe treatments. Its programs address cardiovascular, metabolic, and pulmonary conditions, with a focus on delivering convenient, effective medicines that can offer broad patient impact and commercial potential. Structure Therapeutics conducts its research and development activities across its pipeline within a single organization and seeks to advance clinical candidates through development.

Nuvaira

Series E in 2019
Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

IntoCare

Series B in 2018
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

Wuli Planet

Seed Round in 2018
Health Game Advice: Resist bad games, refuse pirated games, pay attention to self-protection, beware of being deceived, moderate games to benefit the brain, indulge in game injuries, arrange time properly and enjoy a healthy life.

Wuxi Vision Pro

Series B in 2018
Wuxi Vision Pro Ltd. is a prominent manufacturer of ophthalmic medical devices, specializing in the research, development, production, and marketing of intraocular lenses and related products. Established in 2010 and headquartered in Wuxi, China, with an additional location in Irvine, California, the company is dedicated to advancing eye care worldwide. Its portfolio features high refractive index hydrophobic acrylic biocompatible materials, which are crucial for the production of sophisticated ophthalmic devices. Wuxi Vision Pro focuses on developing high-quality lenses aimed at treating various ophthalmic conditions, including cataracts, glaucoma, and retinal diseases. The company prides itself on maintaining rigorous standards in research, development, and quality control to ensure the efficacy and reliability of its products for the global ophthalmic industry.

Qiagen Suzhou Translational Medicine

Series A in 2017
QIAGEN Suzhou is an innovative start-up providing precision medicine solutions.

IntoCare

Series A in 2017
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

LIH Investment & Management

Series A in 2017
LIH Investment & Management manages and invests in rehabilitation medical institutions. The Company serves customers in China. LIH Investment & Management has always been devoted to invest, manage and operate high-quality rehabilitation medical service organization, introduce internationalization concept, technology and mode into China, promote the professional medical rehabilitation service and management and continuous innovation.

LIH Investment & Management

Series A in 2016
LIH Investment & Management manages and invests in rehabilitation medical institutions. The Company serves customers in China. LIH Investment & Management has always been devoted to invest, manage and operate high-quality rehabilitation medical service organization, introduce internationalization concept, technology and mode into China, promote the professional medical rehabilitation service and management and continuous innovation.

JHT TCM Clinics

Series B in 2016
JHT TCM Clinics

Wuxi Vision Pro

Series A in 2015
Wuxi Vision Pro Ltd. is a prominent manufacturer of ophthalmic medical devices, specializing in the research, development, production, and marketing of intraocular lenses and related products. Established in 2010 and headquartered in Wuxi, China, with an additional location in Irvine, California, the company is dedicated to advancing eye care worldwide. Its portfolio features high refractive index hydrophobic acrylic biocompatible materials, which are crucial for the production of sophisticated ophthalmic devices. Wuxi Vision Pro focuses on developing high-quality lenses aimed at treating various ophthalmic conditions, including cataracts, glaucoma, and retinal diseases. The company prides itself on maintaining rigorous standards in research, development, and quality control to ensure the efficacy and reliability of its products for the global ophthalmic industry.

JHT TCM Clinics

Series A in 2013
JHT TCM Clinics

Guokang Health Management

Series B in 2010
Guokang Health Management Co., Ltd., established in Shenzhen, China in 2005, specializes in professional health management services and insurance brokerage. It offers a wide array of services including general practitioner consultations, illness management, chronic disease monitoring, family health management, clinic services, medical examination coordination, health records management, insurance services, and health checkups. Guokang caters to diverse sectors such as corporate, financial, Internet, high-tech, banking, and insurance industries, serving over 600,000 members nationwide through its online platform and extensive service agent network.

Aeonmed Medical Treatment

Series A in 2010
Aeonmed Medical Treatment is a manufacturer and supplier specializing in operating theatre and intensive care unit (ICU) devices. The company focuses on developing a range of medical equipment, including anesthesia machines, operating beds, infusion pumps, mechanical ventilation systems, and nebulizers. Additionally, Aeonmed offers comprehensive medical treatment system solutions that encompass anesthesia and operation support, emergency and critical care, and medical engineering equipment. Their product offerings also include five major medical system solutions, such as laminar flow monitoring and centralized gas supply. Since its inception, Aeonmed has prioritized clinical demands and innovation, resulting in a robust portfolio of over 600 authorized patents, with more than 400 being invention patents, reflecting a commitment to advancing healthcare technology.

Guokang Health Management

Series A in 2007
Guokang Health Management Co., Ltd., established in Shenzhen, China in 2005, specializes in professional health management services and insurance brokerage. It offers a wide array of services including general practitioner consultations, illness management, chronic disease monitoring, family health management, clinic services, medical examination coordination, health records management, insurance services, and health checkups. Guokang caters to diverse sectors such as corporate, financial, Internet, high-tech, banking, and insurance industries, serving over 600,000 members nationwide through its online platform and extensive service agent network.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.